

SUPPORTING INFORMATION

Total Synthesis of Cyclic Heptapeptide Rolloamide B

Mirna El Khatib,^a Mohamed Elagawany,^{a,b,c} Eray Çalışkan,^a Emily Faith Davis,^a Hassan M. Faidallah,^d Said A. El-feky,^b Alan R. Katritzky^{*a,d}

^a*Center for Heterocyclic Compounds, Department of Chemistry, University of Florida, Gainesville, FL 32611-7200, USA.*

^b*Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig-44519, Egypt*

^c*Department of Organic Chemistry, College of Pharmacy, Misr University for Science and Technology, Al-Motamayez District, 6th of October, P.O. Box: 77, Egypt*

^d*Department of Chemistry, King Abdulaziz University, Jeddah, 21589, Saudi Arabia*

^{*}E-mail: katritzky@chem.ufl.edu

TABLE OF CONTENTS


	<u>page</u>
I-Experimental Section	3
A-General	3
B-General Procedure for the Preparation of <i>N</i> -(<i>Z</i> - α -Aminoacyl)benzotriazoles (Method A).....	3
C-General Procedure for the Preparation of <i>N</i> -(Boc- α -Aminoacyl)benzotriazoles using DCC (Method B).	5
D-General Procedure for the Preparation of <i>N</i> -(Boc- α -Aminoacyl)benzotriazoles using BtSO ₂ Me (Method C).....	6
E-General Procedure for the Preparation of Peptides using Benzotriazole Methodology (Method D).	7
F-General Procedure for the Preparation of Peptides (Method E).....	12
G-General Procedure for the deprotection of Boc- protecting group (Method F). ..	14
H-General Procedure for the Macrocyclization of Linear Heptapeptide (Method G).	17
I-General Procedure for Ester Hydrolysis of Linear Heptapeptide (Method H).	18
J-General Procedure for the deprotection of the Cbz- and Bz- protecting group (Method I).	20
II-References	21
III- ¹ H and ¹³ C NMR spectra for all compounds	22

I-Experimental Section


A-General

Melting points were determined on a capillary point apparatus equipped with a digital thermometer and are uncorrected. NMR spectra were recorded with TMS for ^1H (300 MHz) and ^{13}C (75 MHz) as an internal reference. Reaction progress was monitored by thin-layer chromatography (TLC) and visualized by UV light. Elemental analyses were performed on a Carlo Erba EA 1108 instrument.

B-General Procedure for the Preparation of *N*-(*Z*- α -Aminoacyl)benzotriazoles (Method A)




Thionyl chloride (0.6 mL, 8.00 mmol, 1.2 equiv) was added to a solution of 1*H*-benzotriazole (3.17 g, 26.67 mmol, 4 equiv) in methylene chloride to give a clear yellow solution that was stirred for 15 min at room temperature. The amino acid (6.67 mmol, 1 equiv) was then added to give a suspension which was stirred at room temperature for the reported time. The suspension was filtered, the filtrate evaporated, the residue dissolved in EtOAc and the solution was washed with a saturated solution of sodium carbonate. The organic portion was dried over anhyd Na_2SO_4 , filtered, and dried to give the corresponding *N*-(*Z*- α -aminoacyl)benzotriazole.



(S)-Benzyl 2-(1H-benzo[d][1,2,3]triazole-1-carbonyl)pyrrolidine-


1-carboxylate (7a).¹ Stirred for 12 h at room temperature. Yellow oil (77%). ¹H NMR (CDCl₃): δ 8.23 (d, J = 12 Hz, 1H), 8.11 (d, J = 12.9 Hz, 1H), 7.62 (t, J = 12.6 Hz, 1H), 7.48 (t, J = 11.4 Hz, 1H), 7.40-7.17 (m, 10H), 7.01-6.95 (m, 2H), 5.29-4.91 (m, 3H), 4.51-4.42 (m, 1H), 3.81-3.45 (m, 3H), 2.21-1.93 (m, 7H); ¹³C NMR (CDCl₃): δ 176.2, 175.6, 171.5, 171.0, 155.7, 155.2, 154.8, 154.3, 145.8, 138.4, 136.4, 136.3, 135.7, 131.2, 131.0, 131.7, 130.6, 128.5, 128.5, 128.3, 128.1, 128.0, 127.8, 127.8, 127.5, 127.4, 126.5, 126.4, 126.1, 120.2, 120.1, 114.8, 114.3, 114.3, 67.4, 60.0, 59.3, 59.3, 58.9, 47.4, 47.0, 46.6, 31.5, 30.9, 30.7, 29.7, 24.4, 24.3, 23.7, 23.4.




(S)-Benzyl 2-(((S)-1-(1H-benzo[d][1,2,3]triazol-1-yl)-4-methyl-

1-oxopentan-2-yl)carbamoyl)pyrrolidine-1-carboxylate (9a). Stirred for 4 h at 0 °C. Yellow solid (70%); m.p. 74 °C. Converted to compound **10a** after checking NMR; ¹H NMR (CDCl₃): δ 8.30-8.21 (m, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.70-7.62 (m, 1H), 7.55-7.48 (m, 1H), 7.40-7.10 (m, 6H), 5.99-5.94 (m, 1H), 5.23-5.13 (m, 2H), 4.61-4.30 (m, 1H), 3.68-3.30 (m, 2H), 2.40-1.40 (m, 7H), 1.18-0.70 (m, 6H); ¹³C NMR (CDCl₃): δ rotamers: 175.5, 172.4, 172.0, 146.1, 136.2, 131.3, 130.7, 128.7, 128.3, 128.0, 126.5, 126.4, 126.5, 120.4, 114.6, 67.7, 60.7, 60.6, 52.1, 47.3, 47.2, 41.6, 41.2, 31.3, 29.0, 28.5, 25.6, 25.5, 25.1, 24.8, 23.4, 23.1, 22.0, 21.9, 21.6.

C-General Procedure for the Preparation of *N*-(Boc- α -Aminoacyl)benzotriazoles using DCC (Method B).




Boc-protected amino acid (0.03 mol) was added to a solution of DCC (1 equiv) in methylene chloride under an atmosphere of nitrogen. After 30 minutes, BtH (1 equiv) was added and this was stirred for 12 h. The suspension was filtered on a bed of silica and celite, the filtrate evaporated, and the residue dissolved in EtOAc, then filtered on a bed of silica and celite and washed with a solution of saturated sodium carbonate, then with water and brine. The organic portion was dried over anhyd Na_2SO_4 , filtered on a bed of silica, and dried to give the corresponding *N*-(Boc- α -aminoacyl) benzotriazole. ^1H NMR and mp of Boc-L-Phe-Bt **14** matched that reported in the literature.²



(*S*)-*tert*-Butyl (1-(1H-benzo[d][1,2,3]triazol-1-yl)-1-oxo-3-


phenylpropan-2-yl)carbamate (**13**).² White solid (88%). m.p. 114.0-116.0 °C; ^1H NMR and ^{13}C NMR matched that reported in literature.²




(*S*)-tert-Butyl (1-(1H-benzo[d][1,2,3]triazol-1-yl)-3-(benzyloxy)-1-oxopropan-2-yl)carbamate (18b).

Colorless oil (75%). Converted to compound **20** after checking NMR; ^1H NMR (CDCl_3): δ 8.29 (d, $J = 8.1$ Hz, 1H), 8.11 (d, $J = 8.1$ Hz, 1H), 7.68 (t, $J = 7.6$ Hz, 1H), 7.53 (t, $J = 7.6$ Hz, 1H), 7.18-7.05 (m, 5H), 5.85-5.73 (m, 2H), 4.51 (d, $J = 12.3$ Hz, 1H), 4.40 (d, $J = 12.3$ Hz, 1H), 4.20 (dd, $J = 9.5, 3.2$ Hz, 1H), 3.97 (dd, $J = 9.9, 3.0$ Hz, 1H), 1.48 (s, 9H); ^{13}C NMR (CDCl_3): δ 169.6, 155.6, 146.0, 137.1, 131.3, 130.8, 128.4, 127.9, 127.7, 126.6, 120.4, 114.6, 80.6, 73.3, 70.0, 55.3, 28.5; Anal. Calcd for $\text{C}_{21}\text{H}_{24}\text{N}_4\text{O}_4$: C, 63.62; H, 6.10; N 14.13. Found: C, 63.83; H, 6.49; N 13.68.

D-General Procedure for the Preparation of *N*-(Boc- α -Aminoacyl)benzotriazoles using BtSO_2Me (Method C).




A mixture of Boc-protected amino acid (4.646 mmol), 1-(methylsulfonyl)-1H-benzo[d][1,2,3]triazole (0.9 g, 4.646 mmol) and TEA (0.7 g, 6.969 mmol) in DMF was heated in microwave at 50 °C, 50 W for 1 h. The reaction mixture was poured onto cold Na_2CO_3 solution and extracted with ethyl acetate. The organic layer was extracted twice with water and brine. The organic layer was dried over Na_2SO_4 , filtered and filtrate evaporated to give the corresponding *N*-(Boc- α -aminoacyl) benzotriazole.




(S)-tert-Butyl 2-(1H-benzo[d][1,2,3]triazole-1-carbonyl)pyrrolidine-1-

carboxylate (7b). Colorless oil (81%). Converted to compound **8b** after checking NMR. ^1H NMR (CDCl_3): δ 8.34-8.27 (m, 1H), 8.18-8.10 (m, 1H), 7.74-7.62 (m, 1H), 7.59-7.48 (m, 1H), 5.84-5.76 (m, 1H), 3.80-3.63 (m, 2H), 2.65-2.52 (m, 1H), 2.23-2.02 (m, 3H), 1.49 (s, 4H), 1.21 (s, 5H); ^{13}C NMR (CDCl_3): δ 172.3, 171.6, 154.5, 153.6, 146.0, 131.4, 131.2, 130.8, 130.5, 126.5, 126.3, 125.5, 120.4, 120.2, 114.7, 114.4, 80.4, 66.0, 59.7, 59.4, 47.2, 46.9, 31.6, 30.8, 28.6, 28.2, 24.7, 24.1, 15.4, 14.4.


E-General Procedure for the Preparation of Peptides using Benzotriazole Methodology (Method D).




N-(Pg- α -Aminoacyl)benzotriazoles (1.0 mmol) in MeCN (5 mL) was added dropwise to a solution of free amino acid (2 equiv; for AA-OEt, 1 equiv should be used) and Et_3N (or DIPEA, as noted in paper)(2.5-3.5 equiv) in MeCN/ H_2O (9:1, 15 mL) at the temperature reported for each reaction and stirred until all the *N*-(Pg- α -aminoacyl)benzotriazoles were consumed. MeCN was evaporated and the residue dissolved in EtOAc (50 mL) and washed with 3N HCl (5 x 50 mL). The organic portion was dried over anhyd. NaSO_4 , filtered and concentrated to give the desired peptide fragment. No further purification was required in all cases.



(S)-2-((S)-1-((Benzyloxy)carbonyl)pyrrolidine-2-carboxamido)-4-methylpentanoic acid (8a).³ Yellow oil (69%). ¹H NMR (CDCl₃): δ 7.52-7.32 (m, 5H), 5.17 (br s, 2H), 4.53 (br s, 1H), 4.39 (br s, 1H), 3.58-3.38 (m, 2H), 2.00-1.81 (m, 2H), 1.73-1.46 (m, 3H), 0.92-0.88 (m, 6H); ¹³C NMR (CDCl₃): δ rotamers 176.7, 176.3, 175.4, 172.1, 156.5, 156.0, 136.3, 135.8, 129.5, 128.7, 128.6, 128.3, 128.2, 128.0, 127.2, 127.1, 67.2, 66.0, 60.7, 56.3, 54.8, 51.1, 41.1, 38.5, 37.9, 24.9, 22.9, 22.0, 20.9, 15.2, 14.3.




(S)-2-((S)-1-(tert-Butoxycarbonyl)pyrrolidine-2-carboxamido)-4-methylpentanoic acid (8b).⁴ White sticky solid (73%). ¹H NMR (CDCl₃): δ 9.45 (br s, 1H), 7.44 (br s, 1H), 6.82 (br s, 1H), 4.59 (br s, 1H), 4.32 (br s, 1H), 3.52-3.33 (m, 2H), 2.32-2.18 (m, 1H), 1.94-1.84 (m, 2H), 1.73-1.57 (m, 4H), 1.45 (s, 9H), 0.93 (s, 6H); ¹³C NMR (CDCl₃): δ 176.1, 173.2, 172.6, 156.0, 155.5, 81.5, 80.8, 61.2, 59.8, 59.1, 50.9, 47.2, 41.3, 31.3, 28.5, 28.4, 25.0, 23.8, 23.1, 21.9.



(S)-2-((S)-2-((S)-1-((Benzyloxy)carbonyl)pyrrolidine-2-carboxamido)-4-methylpentanamido)-3-phenylpropanoic acid (10a).⁵ Colorless oil (81%). ¹H NMR (CDCl₃): δ 8.10 (br s, 1H), 7.34-7.14 (m, 10H), 5.30-5.02 (m, 3H), 4.40-4.18 (m, 4H), 2.20-2.17 (m, 2H), 2.00-1.88 (m, 4H), 1.60-1.26 (m, 5H), 0.98-0.82 (m, 6H); ¹³C NMR (CDCl₃):


δ 136.4, 129.7, 129.6, 128.8, 128.7, 128.4, 128.1, 127.1, 68.0, 67.8, 67.2, 59.2, 47.2, 46.7, 39.1, 30.8, 30.2, 29.9, 29.2, 25.1, 25.0, 24.5, 24.2, 23.7, 23.2, 23.0, 22.0, 21.9, 14.3.



(S)-1-((S)-2-((*tert*-Butoxycarbonyl)amino)-3-


phenylpropanoyl)pyrrolidine-2-carboxylic acid (14a).⁵ Colorless oil (85%). ¹H NMR

(CDCl₃): δ 9.13 (br s, 1H), 7.42-7.18 (m, 5H), 5.76-5.73 (m, 1H), 4.67-4.64 (m, 1H), 4.55-4.51 (m, 1H), 3.65-3.62 (1H), 3.18-2.90 (m, 3H), 2.15-2.02 (m, 3H), 1.91-1.21 (m, 9H); ¹³C NMR (CDCl₃): δ 176.0, 174.6, 172.1, 155.6, 136.3, 129.8, 128.5, 126.9, 80.0, 59.3, 53.6, 47.3, 38.9, 28.8, 28.5, 24.9, 22.2, 21.0.



(S)-Ethyl 1-((S)-2-((*tert*-butoxycarbonyl)amino)-3-

phenylpropanoyl)pyrrolidine-2-carboxylate (14b). Stirred for 16 h at -40 °C → rt. Colorless oil (90%). ¹H NMR (CDCl₃): δ 7.30-7.15 (m, 5H), 5.40-5.37 (m, 1H), 4.22-4.18 (m, 1H), 3.71-3.53 (m, 1H), 2.85-3.2 (m, 2H), 1.80-2.00 (m, 2H), 1.40-1.22 (m, 12 H); ¹³C NMR (CDCl₃): δ rotamers 171.9, 170.9, 155.4, 136.5, 129.8, 129.5, 128.6, 128.4, 127.0, 126.8, 79.7, 61.9, 61.3, 59.4, 59.2, 54.0, 53.4, 52.3, 47.0, 39.1, 30.7, 29.2, 28.4, 25.0, 22.3, 20.9, 14.3 Anal. Calcd for C₂₁H₃₀N₂O₅: C, 64.60; H, 7.74; N 7.17. Found: C, 64.29; H, 8.04; N 6.95.




(*S*)-1-((*S*)-2-((*S*)-2-((*S*)-1-

((Benzyloxy)carbonyl)pyrrolidine-2-carboxamido)-4-methylpentanamido)-3-

phenylpropanoyl)pyrrolidine-2-carboxylic acid (16a). Stirred for 18 h at -78 °C → rt.


Colorless oil (75%). ¹H NMR (CDCl₃): δ 7.40-7.25 (m, 10H), 5.20-5.14 (m, 2H), 4.30-3.35 (m, 3H), 2.20-2.05 (m, 2H), 2.00-1.80 (m, 4H), 1.80-1.40 (m, 4H), 1.30-1.00 (m, 6H), 0.95-0.85 (m, 6H); ¹³C NMR (CDCl₃): δ 176.3, 172.9, 130.1, 129.1, 128.7, 128.5, 126.6, 115.6, 68.1, 50.1, 41.6, 34.3, 30.3, 26.1, 25.4, 23.4, 22.5, 14.7.



(2*S*,3*S*)-2-((*S*)-3-(Benzyloxy)-2-((tert-

butoxycarbonyl)amino)propanamido)-3-methylpentanoic acid (19). Sticky solid/gel (80%).

Converted to compound **21** after checking NMR; ¹H NMR (CDCl₃): δ 11.15 (br s, 1H), 7.34-7.24 (m, 6H), 5.70 (br s, 1H), 4.61 (dd, *J* = 8.5, 4.4 Hz, 1H), 4.51 (s, 2H), 4.40 (br s, 1H), 3.87 (dd, *J* = 9.3, 3.9 Hz, 1H), 3.60 (dd, *J* = 9.3, 6.6 Hz, 1H), 1.97-1.86 (m, 1H), 1.43 (s, 9H), 1.27-1.02 (m, 2H), 0.90-0.82 (m, 6H); ¹³C NMR (CDCl₃): δ 174.7, 170.9, 155.7, 137.3, 128.4, 127.8, 127.6, 80.4, 73.4, 69.8, 56.7, 53.9, 37.7, 28.2, 24.8, 15.5, 15.4, 11.6.



(6*S*,9*S*,12*S*)-9-((Benzoyloxy)methyl)-6,12-di((*S*)-sec-butyl)-2,2-

dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazatridecan-13-oic acid (5). Required microwave

irradiation at 50 W, 50 °C for 1.5 h. White solid (65%). mp 75.0-77.0 °C; ¹H NMR (CDCl₃): δ

7.39-7.20 (m, 5H), 5.38 (br s, 1H), 4.75-4.68 (m, 1H), 4.57-4.53 (m, 3H), 4.14-4.06 (m, 1H),


3.87-3.82 (m, 1H), 3.61-3.54 (m, 1H), 1.97-1.81 (m, 2H), 1.42 (s, 9H), 1.30-1.04 (m, 4H), 0.93-

0.82 (m, 12H); ¹³C NMR (CDCl₃): δ 174.4, 172.4, 170.3, 156.2, 137.4, 128.6, 128.0, 80.3, 73.6,


69.6, 59.5, 57.2, 52.6, 37.5, 28.4, 25.1, 24.8, 15.7, 15.6, 11.7, 11.5; Anal. Calcd for C₂₇H₄₃N₃O₇:

C, 62.17; H, 8.31; N 8.06. Found: C, 62.17; H, 8.61; N 7.83.

F-General Procedure for the Preparation of Peptides (Method E).⁶



A solution of the amino acid with free carboxyl group (3 mmol) in dry THF (10 mL) under argon was cooled to $-15\text{ }^{\circ}\text{C}$ in an ice bath with stirring. N-Methylmorpholine (0.33 g, 3.2 mmol), followed by isobutyl chloroformate (0.45 g, 3.2 mmol) were added. After 4 min, a solution of the amino acid hydrochloride salt (1.5 mmol) and N-methylmorpholine (0.7 g, 1.6 mmol) in DMF (5 mL) was added. The ice bath was removed after 5 min, and the solution was allowed to stir for 12 h at room temperature. The solution was concentrated under vacuum and the residue was dissolved in ethyl acetate (30 mL) and water (5 mL). The organic phase was washed successively with saturated Na_2CO_3 ($2 \times 15\text{ mL}$), water (10 mL), 2N HCl (15 mL), and water (10 mL). The solution was dried over MgSO_4 , filtered, and then concentrated under vacuum. The peptide was recrystallized from ethyl acetate–hexanes to give the desired peptide.




(S)-tert-Butyl 2-(((S)-1-(((S)-1-((S)-2-

(ethoxycarbonyl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)amino)-4-methyl-1-

oxopentane-2-yl)carbamoyl)pyrrolidine-1-carboxylate (16b). White solid (83%). mp $81.0\text{--}83.0$

$^{\circ}\text{C}$; ^1H NMR (CD_3OD): δ 7.34–7.19 (m, 5H), 4.43–4.36 (m, 2H), 4.21–4.13 (m, 3H), 3.75–3.67

(m, 1H), 3.52-3.34 (m, 3H), 3.12 (dd, $J = 14.1, 6.3$ Hz, 1H), 2.91 (dd, $J = 14.1, 7.5$ Hz, 1H), 2.24-2.13 (m, 1H), 2.00-1.79 (m, 6H), 1.76-1.60 (m, 2H), 1.52-1.35 (m, 12H), 1.26 (t, $J = 7.2$ Hz, 3H), 0.96-0.87 (m, 6H); ^{13}C NMR (CD_3OD): δ 175.5, 175.3, 174.4, 173.4, 172.8, 172.1, 171.9, 156.5, 156.1, 138.1, 137.7, 130.7, 130.6, 129.8, 129.6, 128.3, 127.9, 81.4, 62.3, 61.3, 60.8, 60.7, 54.0, 54.0, 53.1, 48.0, 47.5, 42.4, 38.7, 32.6, 30.2, 28.8, 25.9, 25.9, 24.7, 23.6, 22.2, 14.7; Anal. Calcd for $\text{C}_{32}\text{H}_{48}\text{N}_4\text{O}_7$: C, 63.98; H, 8.05; N 9.33. Found: C, 63.68; H, 8.32; N 8.64.




(*S*)-Ethyl 1-((*S*)-2-((*S*)-2-((*S*)-1-((6*S*,9*S*,12*S*)-9-


((benzyloxy)methyl)-6,12-di((*S*)-sec-butyl)-2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazatriecan-13-oyl)pyrrolidine-2-carboxamido)-4-methylpentanamido)-3-

phenylpropanoyl)pyrrolidine-2-carboxylate (3). White solid (81%). mp 74.0-76.0 °C; ^1H NMR (CDCl_3): δ 7.25-7.09 (m, 10H), 4.85 (br s, 1H), 4.72-4.63 (m, 1H), 4.55-4.32 (m, 4H), 4.22 (br s, 1H), 4.14-4.00 (m, 2H), 3.90-3.72 (m, 3H), 3.70-3.20 (m, 5H), 3.10-2.95 (m, 1H), 2.89-2.79 (m, 1H), 2.16-1.75 (m, 9H), 1.60-1.41 (m, 4H), 1.34 (s, 9H), 1.19 (t, $J = 7.1$ Hz, 3H), 1.13-1.04 (m, 4H), 0.88-0.70 (m, 18H); ^{13}C NMR (CDCl_3): δ 174.3, 173.6, 171.9, 171.7, 170.1, 169.9, 169.6, 155.8, 137.4, 136.2, 129.7, 129.3, 128.6, 128.3, 127.8, 126.8, 79.8, 73.5, 73.4, 73.3, 71.8, 69.8, 69.6, 61.1, 59.1, 59.0, 52.7, 52.0, 47.0, 38.4, 37.5, 29.0, 28.3, 27.9, 26.2, 24.8, 24.7, 23.0, 22.1, 21.7, 19.0, 15.6, 15.5, 14.4, 14.2, 11.8, 11.7, 11.5; Anal. Calcd for $\text{C}_{54}\text{H}_{83}\text{N}_7\text{O}_{12}$: C, 63.44; H, 8.18; N 9.15. Found: C, 63.19; H, 8.63; N 9.12.

G-General Procedure for the deprotection of Boc- protecting group (Method F). ⁷




Boc-Protected amino acid (1.0 mmol) was dissolved in HCl-dioxane (4.0 M HCl in dioxane, 15 mL) and stirred for 1 h. Solvent was evaporated, ether was added to the residue and the suspension was stirred for 2h. Filtration (when sticky solid resulted, decantation of ether several times was performed instead) gave the required amino acid/peptide as a hydrochloride salt.




(S)-1-((S)-2-Carboxypyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-aminium

chloride (15a). White solid (95%). m.p. 119 °C; ¹H NMR (CD₃OD): δ mixture of rotamers 7.31-7.13 (m, 5H), 4.42-4.20 (m, 2H), 3.22-3.09 (m, 2H), 3.02-2.85 (m, 2H), 2.22-2.02 (m, 1H), 1.98-1.62 (m, 2H), 1.60-1.40 (m, 1H); ¹³C NMR (CD₃OD): δ 175.1, 168.9, 135.7, 131.5, 131.0, 130.6, 130.5, 129.3, 68.5, 61.2, 54.8, 48.1, 38.2, 30.5, 26.3. Anal. Calcd for C₂₈H₄₀Cl₂N₄O₇: C, 54.63; H, 6.55; N 9.10. Found: C, 54.19; H, 6.68; N 8.76.




(S)-1-((S)-2-(ethoxycarbonyl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-

aminium chloride (15b).⁸ White hygroscopic solid (97%). ¹H NMR (CDCl₃): δ mixture of rotamers 7.36-7.10 (m, 5H), 4.42-4.25 (m, 1H), 4.20-4.00 (m, 2H), 3.55 (s, 2H), 3.25-3.00 (m, 2H), 3.05-2.90 (m, 2H), 2.01-2.20 (m, 1H), 1.84-1.72 (m, 3H), 1.22-1.16 (m, 3H); ¹³C NMR (CDCl₃): δ 174.5, 168.4, 135.2, 130.9, 130.6, 129.7, 130.1, 130.0, 128.8, 68.1, 64.0, 62.3, 60.8, 54.4, 54.2, 53.0, 48.1, 40.0, 37.8, 31.5, 30.0, 25.9, 23.5, 14.5.




(S)-3-(Benzoyloxy)-1-(((1S,2S)-1-carboxy-2-methylbutyl)amino)-1-

oxopropan-2-aminium chloride (20). Gel (95%); ¹H NMR (CD₃OD): δ 7.39-7.28 (m, 5H), 4.61 (s, 2H), 4.44 (d, J = 5.3 Hz, 1H), 4.21 (dd, J = 6.6, 3.9 Hz, 1H), 3.92 (dd, J = 10.5, 3.9 Hz, 1H), 3.80 (dd, J = 10.5, 6.6 Hz, 1H), 1.98-1.89 (m, 1H), 1.57-1.44 (m, 1H), 1.34-1.20 (m, 1H), 0.99-0.90 (m, 6H); ¹³C NMR (CD₃OD): δ 174.1, 168.0, 138.7, 129.6, 129.2, 129.1, 74.7, 69.4, 58.6, 54.6, 38.5, 26.3, 16.2, 12.1; Anal. Calcd for C₃₂H₅₂Cl₂N₉O₄: C, 54.31; H, 7.41; N 7.92. Found: C, 54.05; H, 7.28; N 7.88.




(S)-2-(((S)-1-(((S)-1-((S)-2-(Ethoxycarbonyl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamoyl)pyrrolidin-1-ium chloride (4b). White solid (87%). m.p. 93.0-95.0 °C; ¹H NMR (CD₃OD): δ 8.38-8.28 (m, 1H), 7.18-7.05 (m, 5H), 4.32-4.22 (m, 2H), 4.17-4.13 (m, 1H), 4.06-3.99 (m, 2H), 3.64-3.55 (m, 1H), 3.31-3.19 (m, 3H), 2.96 (dd, *J* = 14.1, 5.7 Hz, 1H), 2.80-2.73 (m, 1H), 2.33-2.20 (m, 1H), 2.11-1.76 (m, 7H), 1.57-1.35 (m, 4H), 1.11 (t, *J* = 7.2 Hz, 3H), 0.81-0.73 (m, 6H); ¹³C NMR (CD₃OD): δ 173.9, 173.5, 172.0, 169.8, 169.7, 138.1, 137.7, 130.8, 130.6, 129.8, 129.6, 128.4, 127.9, 62.5, 62.4, 61.0, 60.8, 60.7, 53.9, 53.8, 53.7, 48.3, 47.6, 47.5, 41.9, 41.5, 38.6, 32.0, 31.2, 30.2, 26.0, 25.1, 23.5, 22.1, 14.6; Anal. Calcd for C₂₇H₄₃ClN₄O₆: C, 58.42; H, 7.81; N 10.09. Found: C, 58.61; H, 7.98; N 9.54.




(2S,3S)-1-(((S)-3-(Benzoyloxy)-1-(((2S,3S)-1-((S)-2-(((S)-1-(((S)-1-((S)-2-carboxypyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxopentan-2-aminium chloride (23). White solid (91%).

m.p. 115.0-117.0 °C; ^1H NMR (CDCl_3): δ 7.36-7.19 (m, 10H), 4.87-4.79 (m, 2H), 4.58-4.54 (m, 2H), 4.46-4.25 (m, 3H), 3.87-3.70 (m, 5H), 3.58-3.36 (m, 3H), 3.16-3.10 (m, 1H), 2.97-2.88 (m, 1H), 2.23-2.14 (m, 1H), 1.98-1.81 (m, 8H), 1.69-1.49 (m, 4H), 1.43-1.22 (m, 2H), 1.05 (dd, J = 6.9, 2.8 Hz, 2H), 0.98-0.87 (m, 18H); ^{13}C NMR (CDCl_3): δ 175.2, 174.7, 174.3, 174.2, 171.9, 171.5, 169.5, 139.1, 138.1, 130.8, 129.8, 129.5, 129.1, 128.9, 127.8, 74.5, 72.8, 71.5, 71.0, 60.7, 60.6, 59.0, 58.5, 56.0, 54.9, 54.5, 53.8, 53.2, 48.0, 42.0, 42.1, 38.7, 38.5, 38.1, 32.0, 31.0, 30.2, 29.3, 27.4, 26.2, 25.9, 25.5, 24.6, 23.6, 22.3, 19.5, 16.1, 15.2, 12.3, 12.0, 11.8; HRMS (+ESI) m/z for $\text{C}_{47}\text{H}_{70}\text{N}_7\text{O}_9$ $[\text{M} + \text{H}]^+$ calcd. 879.5230, found 879.5057.

H-General Procedure for the Macrocyclization of Linear Heptapeptide (Method G).⁹




A modified literature procedure⁹ was used. FDPP (63 mg, 0.164 mmol, 1.5 equiv) was added to a solution of the linear heptapeptide **23** (100 mg, 0.110 mmol) in acetonitrile (20 mL, 0.005 M) under anhydrous conditions. DIPEA (51 mg, 0.394 mmol, 3.6 equiv) was added to this solution. The reaction mixture was then stirred at rt overnight, then the solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (30 mL) and washed with Na_2CO_3 solution (2x 15 mL). The organic layer was dried over Na_2SO_4 , filtered and concentrated under vacuum to yield cyclized heptapeptide **24**.




((6*S*,9*S*,12*S*,14*aS*,20*S*,23*S*,25*aS*)-20-benzyl-6,12-di(*S*)-sec-butyl)-23-isobutyl-5,8,11,14,19,22,25-heptaioxotetracosahydro-1*H*-dipyrrolo[1,2-*a*:1',2'-*j*][1,4,7,10,13,16,19]heptaazacycloheptacosin-9-yl)methyl benzoate (24**). White solid (74%). m.p. 122-124 °C; ¹H NMR (CDCl₃): δ 7.44-7.16 (m, 10H), 4.75-4.63 (m, 1H), 4.56-4.46 (m, 2H), 4.39-4.16 (m, 3H), 3.80-3.63 (m, 6H), 3.59-3.38 (m, 3H), 3.21-3.06 (m, 1H), 3.01-2.84 (m, 1H), 2.30-2.12 (m, 1H), 2.05-1.76 (m, 8H), 1.68-1.55 (m, 2H), 1.53-1.42 (m, 2H), 1.40-1.28 (m, 3H), 1.02-0.81 (m, 19H); ¹³C NMR (CDCl₃): δ 175.2, 175.2, 174.3, 173.7, 172.1, 139.3, 138.3, 130.7, 129.9, 129.8, 129.6, 129.5, 129.0, 128.9, 128.8, 127.9, 74.4, 72.9, 71.1, 61.7, 61.0, 55.8, 53.3, 43.8, 42.2, 41.7, 38.4, 32.8, 31.5, 30.5, 29.4, 26.2, 25.9, 24.7, 23.6, 22.3, 22.0, 19.6, 18.2, 16.2, 13.3, 12.1, 11.9. HRMS *m/z* for C₄₇H₆₅N₇O₉ [M+H]⁺ calcd. 858.5124, found 858.5115.**

I-General Procedure for Ester Hydrolysis of Linear Heptapeptide (Method H).



Procedure followed was according to a modified literature method.¹⁰ To a solution of Boc-Heptapeptide ethyl ester **3** (400 mg, 0.398 mmol), in methanol (15 mL), THF (9 mL) was added

LiOH (84 mg, 1.992 mmol) dissolved in water (3 mL). The mixture was allowed to stir at room temperature (25 °C) over 2h. Solvent was evaporated from reaction mixture under reduced pressure, dissolved in water and acidified with 2N HCl, extracted with ethyl acetate. The organic layer was dried over anhyd Na₂SO₄ and concentrated to obtain **22**.




(S)-1-((S)-2-((S)-2-((S)-1-((6S,9S,12S)-9-

((Benzoyloxy)methyl)-6,12-di((S)-sec-butyl)-2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazatriecan-13-oyl)pyrrolidine-2-carboxamido)-4-methylpentanamido)-3-


phenylpropanoyl)pyrrolidine-2-carboxylic acid (22). White solid (75%); m.p. 98-99 °C; ¹H NMR (CDCl₃): δ 9.72 (br s, 1H), 7.28-7.10 (m, 10H), 4.86 (br s, 1H), 4.67-4.64 (m, 1H), 4.51-4.41 (m, 4H), 4.23 (br s, 1H), 3.80-3.72 (m, 3H), 3.59-3.34 (m, 4H), 3.10-2.98 (m, 2H), 2.85 (dd, *J* = 13.3, 5.5 Hz, 1H), 2.08-2.01 (m, 1H), 1.93-1.75 (m, 8H), 1.52-1.40 (m, 4H), 1.34 (s, 9H), 1.11-0.92 (m, 4H), 0.87-0.73 (m, 18H); ¹³C NMR (CDCl₃): δ 175.1, 174.6, 174.2, 173.7, 172.3, 170.2, 169.4, 156.5, 156.0, 137.4, 135.9, 129.9, 129.6, 128.5, 127.9, 127.9, 127.0, 80.1, 73.5, 73.4, 71.9, 69.6, 60.5, 59.4, 57.0, 55.8, 52.7, 52.6, 47.4, 41.5, 38.3, 38.0, 37.5, 28.7, 28.4, 28.1, 26.2, 25.0, 24.8, 23.1, 21.9, 21.0, 19.1, 15.7, 15.6, 14.5, 11.9, 11.7, 11.5; ; Anal. Calcd for C₅₂H₈₁N₇O₁₃: C, 61.70; H, 8.07; N 9.69. Found: C, 61.57; H, 8.29; N 8.49.

J-General Procedure for the deprotection of the Cbz- and Bz- protecting group (Method I).



The amino acid/peptide (1.0 mmol) was dissolved in anhydrous MeOH (30 mL) and stirred under an atmosphere of hydrogen in the presence of a catalytic amount of Pd/C for 48 h.

Filtration through a bed of celite and evaporation afforded the desired amino acid/peptide.





(6*S*,9*S*,12*S*,14*aS*,20*S*,23*S*,25*aS*)-20-Benzyl-6,12-di((*S*)-sec-butyl)-9-(hydroxymethyl)-23-isobutylhexadecahydro-1*H*-dipyrrolo[1,2-*a*:1',2'-*j*][1,4,7,10,13,16,19]heptaazacyclohenicosine-5,8,11,14,19,22,25(25*aH*)-heptaone (1). NMR and optical rotation matched reported.¹¹


II-References


1. A. R. Katritzky, P. Angrish and K. Suzuki, *Synthesis*, 2006, 411-424.
2. A. R. Katritzky, A. A. Shestopalov and K. Suzuki, *Synthesis*, 2004, 1806-1813.
3. W. D. Cash, *Journal of Organic Chemistry*, 1961, 26, 2136-2137.
4. A. A. Mazurov, V. M. Kabanov and S. A. Andronati, *Doklady Akademii Nauk SSSR*, 1989, 306, 364-366.
5. S. Salvadori, M. Marastoni, G. Balboni, P. Borea and R. Tomatis, *European Journal of Medicinal Chemistry*, 1990, 25, 171-177.
6. K. Ha, M. Chahar, J.-C. M. Monbaliu, E. Todadze, F. K. Hansen, A. A. Oliferenko, C. E. Ocampo, D. Leino, A. Lillicotch, C. V. Stevens and A. R. Katritzky, *Journal of Organic Chemistry*, 2012, 77, 2637-2648.
7. M. El Khatib, M. Elagawany, F. Jabeen, E. Todadze, O. Bol'shakov, A. Oliferenko, L. Khelashvili, S. A. El-Feky, A. Asiri and A. R. Katritzky, *Organic & Biomolecular Chemistry*, 2012, 10, 4836-4838.
8. J. I. Harris and T. S. Work, *Biochemical Journal*, 1950, 46, 196-199.
9. D. Skropeta, K. A. Jolliffe and P. Turner, *Journal of Organic Chemistry*, 2004, 69, 8804-8809.
10. *Application: WO*
WO Pat., 2011-IB50290
2011089576, 2011.
11. D. E. Williams, K. Yu, H. W. Behrisch, R. Van Soest and R. J. Andersen, *Journal of Natural Products*, 2009, 72, 1253-1257.


III-¹H and ¹³C NMR spectra for all compounds





































8a














C-61





























15a

